With the advent of immunotherapeutic agents, durable and dramatic responses have been observed in several hard-to-treat malignancies, outlining a roadmap to conquering cancer. Immune checkpoint inhibitors (ICPi) are a class of immunotherapeutic agents that attack the tumor cells by reinvigorating the suppressed immune system. However, the unbridled T-cell activity disrupts the immune homeostasis and induces a unique spectrum of side effects called immune-related adverse events (irAEs). These irAEs are distinct from the side effects produced by traditional chemotherapeutic agents. The management of irAEs has been challenging to the patients, caregivers and the healthcare providers alike. With increasing use of ICPis, the incidence of irAEs will undoubtedly increase. There is a compelling need to develop measures and resources to effectively manage irAEs, both in the community settings and in cancer centers alike.